List view / Grid view
respiratory syncytial virus (RSV)
Using nose organoids, researchers have highlighted key differences between the infection by SARS-CoV-2 and that of respiratory syncytial virus.
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
A new study has showed how a bioengineered RSV protein vaccine can induce a protective immune response in animal models.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Scientists have found and characterised the activity of four antibodies produced by the human immune system that targets an important protein found in the respiratory syncytial virus...
'Mini organs' may aid in understanding and treating respiratory diseases.